Automate Your Wheel Strategy on GILD
With Tiblio's Option Bot, you can configure your own wheel strategy including GILD - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol GILD
- Rev/Share 23.7053
- Book/Share 18.211
- PB 8.2275
- Debt/Equity 0.0
- CurrentRatio 1.6834
- ROIC 0.2025
- MktCap 185891084400.0
- FreeCF/Share 7.7778
- PFCF 19.2434
- PE 21.8671
- Debt/Assets 0.0
- DivYield 0.0211
- ROE 0.4101
- Rating B+
- Score 3
- Recommendation Neutral
- P/E Score 3
- DCF Score 4
- P/B Score 1
- D/E Score 1
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Initiation | GILD | Barclays | -- | Equal Weight | -- | $155 | Feb. 20, 2026 |
| Reiterated | GILD | Needham | -- | Buy | $140 | $170 | Feb. 11, 2026 |
| Resumed | GILD | UBS | -- | Buy | -- | $145 | Jan. 7, 2026 |
| Resumed | GILD | Truist | -- | Buy | -- | $140 | Nov. 24, 2025 |
| Initiation | GILD | Scotiabank | -- | Sector Outperform | -- | $140 | Nov. 13, 2025 |
| Upgrade | GILD | Daiwa Securities | Neutral | Outperform | -- | $128 | Aug. 19, 2025 |
| Upgrade | GILD | Truist | Hold | Buy | -- | $127 | Aug. 8, 2025 |
| Upgrade | GILD | Needham | Hold | Buy | -- | $133 | July 25, 2025 |
| Resumed | GILD | Cantor Fitzgerald | -- | Overweight | -- | $125 | April 22, 2025 |
| Reiterated | GILD | Oppenheimer | -- | Outperform | $115 | $132 | March 4, 2025 |
News
GILD to Acquire ACLX for $7.8B & Gain Full Control of Anito-Cel
Published: February 24, 2026 by: Zacks Investment Research
Sentiment: Positive
Gilead is set to acquire Arcellx for $7.8B, gaining full control of anito-cel and boosting its cell therapy pipeline amid rising competition.
Read More
Gilead pays $7.8bn to take full control of promising multiple myeloma therapy
Published: February 23, 2026 by: Proactive Investors
Sentiment: Positive
Gilead Sciences Inc (NASDAQ:GILD, XETRA:GIS) has agreed to buy Arcellx in a deal valuing the clinical-stage biotechnology company at $7.8 billion, converting an existing partnership into outright ownership of a CAR T-cell therapy that could be approved by US regulators before the end of this year. The offer of $115 per share in cash represents a 68% premium to Arcellx's 30-day volume-weighted average share price as of 20 February.
Read More
Gilead shows its belief in its partner's cancer treatment with a $7.8 billion buyout
Published: February 23, 2026 by: Market Watch
Sentiment: Positive
Shares of Arcellx shot up toward a fresh record in early Monday trading, after Gilead Sciences agreed to buy the rest of the shares it doesn't already own of the biotechnology company, in a deal with an equity value of $7.8 billion.
Read More
Gilead Sciences to Buy Arcellx in Deal Valued at $7.8 Billion
Published: February 23, 2026 by: WSJ
Sentiment: Positive
Gilead Sciences has agreed to buy the rest of development partner Arcellx in a deal that values the biotechnology company at about $7.8 billion at closing.
Read More
Gilead to acquire Arcellx for $7.8 billion
Published: February 23, 2026 by: Reuters
Sentiment: Positive
Gilead Sciences said on Monday it will buy cancer therapy developer Arcellx for an implied equity value of $7.8 billion, sending shares of Arcellx climbing 77.8% to $113.99 in premarket trading.
Read More
Gilead Sciences to Acquire Arcellx to Maximize Long-Term Potential of Anito-cel
Published: February 23, 2026 by: Business Wire
Sentiment: Neutral
FOSTER CITY, Calif. & REDWOOD CITY, Calif.--(BUSINESS WIRE)-- #ACLX--Gilead Sciences, Inc. (Nasdaq: GILD) today announced that it has entered into a definitive agreement to acquire Arcellx (Nasdaq: ACLX) for $115 per share in cash at closing and one contingent value right of $5 per share, which represents an implied equity value of $7.8 billion payable at closing. Arcellx is a biotechnology company focused on delivering a new class of innovative immunotherapies for patients with cancer and other incura.
Read More
Gilead Sciences to Acquire Arcellx to Maximize Long-term Potential of Anito-cel
Published: February 23, 2026 by: Business Wire
Sentiment: Neutral
FOSTER CITY, Calif. & REDWOOD CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced that it has entered into a definitive agreement to acquire Arcellx (Nasdaq: ACLX) for $115 per share in cash at closing and one contingent value right of $5 per share, which represents an implied equity value of $7.8 billion payable at closing. Arcellx is a biotechnology company focused on delivering a new class of innovative immunotherapies for patients with cancer and other incura.
Read More
Time To Take Profits On Gilead Sciences (Rating Downgrade)
Published: February 20, 2026 by: Seeking Alpha
Sentiment: Negative
Gilead Sciences, Inc. shares have risen more than 43% over the past year. I continue to believe that its three key drugs remain Biktarvy, Yeztugo, and Livdelzi, whose total sales grew 10.8% year-over-year to $4.2 billion in Q4. On the other hand, sales of Gilead's oncology franchise leave much to be desired, despite its numerous attempts to compete with Merck, Pfizer, and AstraZeneca.
Read More
Is Most-Watched Stock Gilead Sciences, Inc. (GILD) Worth Betting on Now?
Published: February 19, 2026 by: Zacks Investment Research
Sentiment: Positive
Gilead (GILD) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Read More
Gilead Sciences (GILD) is a Top-Ranked Momentum Stock: Should You Buy?
Published: February 13, 2026 by: Zacks Investment Research
Sentiment: Positive
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Read More
Can Gilead's HIV Portfolio Sustain Its Growth Trend in 2026?
Published: February 13, 2026 by: Zacks Investment Research
Sentiment: Positive
Gilead Sciences posts strong 2025 HIV growth despite a $900M headwind, as Biktarvy and Descovy lead and new launch Yeztugo gains momentum.
Read More
Focus on These 5 Stocks That Recently Hiked Dividends
Published: February 13, 2026 by: Zacks Investment Research
Sentiment: Positive
NTES joins four peers in lifting dividends as resilient markets, rate-cut hopes and volatility spur investors toward steady income plays.
Read More
GILD's Q4 Earnings Beat Estimates, HIV and Liver Disease Drugs Power Sales
Published: February 11, 2026 by: Zacks Investment Research
Sentiment: Positive
Gilead beats Q4 estimates on strong HIV and Liver Disease portfolio performance, but 2026 guidance tempers sentiment despite Yeztugo's solid debut.
Read More
Gilead Sciences Stock Surges to Record Highs Amid Bull Notes
Published: February 11, 2026 by: Schaeffers Research
Sentiment: Positive
Gilead Sciences Inc (NASDAQ:GILD) stock is up 5.7%, hitting a record high of $155.56 at last glance, after the biopharmaceutical company announced a top- and bottom-line win for the fourth quarter.
Read More
Will These 5 Drug Bigwigs Surpass Q4 Earnings Forecasts?
Published: February 09, 2026 by: Zacks Investment Research
Sentiment: Positive
Let's look at five pharma and biotech companies, AZN, INCY, GILD, VRTX and MRNA, which are scheduled to release their fourth-quarter 2025 results this week.
Read More
Should You Buy, Hold, or Sell GILD Stock Ahead of Q4 Earnings?
Published: February 05, 2026 by: Zacks Investment Research
Sentiment: Neutral
GILD readies Q4 results as HIV drugs Biktarvy and Descovy drive growth, while Yeztugo uptake and cell therapy headwinds shape expectations.
Read More
Ahead of Gilead (GILD) Q4 Earnings: Get Ready With Wall Street Estimates for Key Metrics
Published: February 05, 2026 by: Zacks Investment Research
Sentiment: Positive
Looking beyond Wall Street's top-and-bottom-line estimate forecasts for Gilead (GILD), delve into some of its key metrics to gain a deeper insight into the company's potential performance for the quarter ended December 2025.
Read More
Earnings Preview: Gilead Sciences (GILD) Q4 Earnings Expected to Decline
Published: February 03, 2026 by: Zacks Investment Research
Sentiment: Negative
Gilead (GILD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Read More
Here's Why Gilead Sciences Stock Surged 21% in a Month
Published: February 03, 2026 by: Zacks Investment Research
Sentiment: Positive
GILD shares gain traction post Jan. 20 after NEJM data show Trodelvy plus Keytruda cut progression risk 35% in first-line PD-L1+ metastatic TNBC, signaling a new care standard.
Read More
Gilead Sciences, Inc. (GILD) is Attracting Investor Attention: Here is What You Should Know
Published: January 28, 2026 by: Zacks Investment Research
Sentiment: Positive
Recently, Zacks.com users have been paying close attention to Gilead (GILD). This makes it worthwhile to examine what the stock has in store.
Read More
Gilead Sciences: Margin Expansion And Cash Flow Strength Underpriced
Published: January 20, 2026 by: Seeking Alpha
Sentiment: Positive
Gilead Sciences is undervalued, with a Buy rating and a DCF-based target price of $141, implying 13.4% upside. Core HIV business remains stable, while new product launches and acquisitions, notably Livdelzi, drive incremental growth and diversification. Q3 2025 results exceeded expectations, with revenue up 4% YoY and non-GAAP EPS up 22%, highlighting strong operational efficiency and margin expansion.
Read More
Gilead: A Top GARP Biotech Play, But Momentum Weakens (Downgrade)
Published: January 16, 2026 by: Seeking Alpha
Sentiment: Positive
Gilead Sciences is downgraded from "Strong Buy" to "Buy" as technical momentum has softened despite robust fundamentals. Q3 results exceeded expectations, with EPS of $2.47 and revenue of $7.8 billion, driven by HIV franchise outperformance. GILD guides for 2025 sales of $28.4–$28.7 billion and EPS of $8.05–$8.25, with HIV revenue forecast above $20B and a strong pipeline.
Read More
Gilead Sciences, Inc. (GILD) Is a Trending Stock: Facts to Know Before Betting on It
Published: January 14, 2026 by: Zacks Investment Research
Sentiment: Positive
Gilead (GILD) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Read More
Gilead Sciences, Inc. (GILD) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Published: January 12, 2026 by: Seeking Alpha
Sentiment: Neutral
Gilead Sciences, Inc. (GILD) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Read More
Gilead Sciences CEO Daniel O'Day: We have the most robust pipeline in company history
Published: January 12, 2026 by: CNBC Television
Sentiment: Positive
Daniel O'Day, Gilead Sciences CEO and chairman, joins 'Squawk Box' to discuss the advances in medicine, what to expect at the JPMorgan Healthcare Conference today, the company's Yeztugo HIV medication, drug pipeline outlook, impact of AI, and more.
Read More
Here's Why Gilead Sciences (GILD) is a Strong Momentum Stock
Published: January 07, 2026 by: Zacks Investment Research
Sentiment: Positive
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Read More
3 Cash-Flow Machines Investors May Want Heading Into 2026
Published: January 02, 2026 by: MarketBeat
Sentiment: Neutral
Of the host of financial metrics investors might consider when deciding whether to buy shares of a target company, cash flow is among the most important. Operating cash flow is a reflection of how a firm actually functions on a day-to-day basis and demonstrates the company's ability to bring in money from sales or other sources and to adequately pay salaries, taxes, and other expenses.
Read More
GILD Exercises Option to License Assembly Bio's Herpes Programs
Published: December 23, 2025 by: Zacks Investment Research
Sentiment: Neutral
Gilead exercises its option to license ASMB's HSV programs for developing long-acting candidates, ABI-1179 & ABI-5366, for recurrent genital herpes.
Read More
Drug Sector on a High as 9 Drugmakers Strike Drug Pricing Deals
Published: December 22, 2025 by: Zacks Investment Research
Sentiment: Positive
Amgen and eight other pharma giants struck deals with the Trump administration to cut U.S. drug prices while gaining tariff relief and manufacturing incentives.
Read More
Gilead Sciences Exercises Option to License Assembly Biosciences' Helicase-Primase Inhibitor Programs for Recurrent Genital Herpes
Published: December 22, 2025 by: Business Wire
Sentiment: Neutral
FOSTER CITY, Calif. & SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) and Assembly Biosciences, Inc. (Nasdaq: ASMB), today announced Gilead has exercised its combined option to exclusively license Assembly Bio's herpes simplex virus (HSV) helicase-primase inhibitor programs, including long-acting investigational candidates ABI-1179 and ABI-5366 for recurrent genital herpes. These represent the first programs Gilead will advance under the ongoing Assembly Bio R.
Read More
About Gilead Sciences, Inc. (GILD)
- IPO Date 1992-01-22
- Website https://www.gilead.com
- Industry Drug Manufacturers - General
- CEO Daniel O'Day
- Employees 17600